Mepolizumab
Mepolizumab
Definition
A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. Upon subcutaneous administration, mepolizumab selectively binds to IL-5, preventing it from associating with interleukin-5 receptor subunit alpha (IL5RA) on the surface of eosinophils and their progenitors. IL-5 plays a role in the regulation of eosinophil development from hematopoietic progenitors as well as eosinophil maturation, differentiation, mobilization, activation, and survival. IL-5 also play a role in the pathogenesis of some phenotypes of hypereosinophilic syndrome (HES).
Also known as Bosatria, MEPOLIZUMAB, Nucala, SB 240563, SB-240563, SB240563 — per NCIT
Also identified as
- ATC R03DX09 per RXNORM
- NCIT NCIT:C157376 per NCIT
- SCTID 716046009 per RXNORM
- SCTID 781308003 per RXNORM
- UNII 90Z2UF0E52 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Asthma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Respiratory system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.